Financial Astrology Terminal

Johnson & Johnson (JNJ) Stock Analysis 2027

An informational overview of Johnson & Johnson's healthcare business, operating measures and risks.

JNJ stockPharmaceuticalsCompany analysis
Johnson & Johnson (JNJ) analysis illustration
JNJ snapshot · as of November 6, 2026 (close) · Stock quote pages
$276.22
Market capitalization
$664.95B
Dividend yield
~1.86%
52-week low
$185.12
52-week high
$282.02

Company Overview

Johnson & Johnson is a diversified healthcare company that reports two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). It trades on the NYSE under the ticker JNJ. It separated its consumer health business into Kenvue in 2023.

Johnson & Johnson was founded in 1886 and became one of the largest healthcare companies in the world.

In 2023 it separated its consumer health brands into Kenvue to focus on pharmaceuticals and medical devices.

Latest Quarterly Results: Q3 2026

Johnson & Johnson reported third-quarter 2026 results on October 13, 2026.

Q3 2026 sales
$25.40B
+5.9% year over year
GAAP net earnings
$210M
vs $5.15B; includes a one-time talc-related charge
Adjusted diluted EPS
$2.59
GAAP $0.09
Innovative Medicine sales
$16.8B
+7.7%
MedTech sales
$8.6B
+2.5%
Company outlook, 2026 sales
~$101.2B
management guidance midpoint, raised
Quarterly Sales
USD billions, Q3 2025 vs Q3 2026

GAAP earnings fell sharply because of a special charge tied to a proposed talc litigation resolution, plus acquisition and collaboration costs, while adjusted earnings were much higher. Separating one-time items from ongoing results is important when reading this quarter.

Tremfya sales rose 68% to $2.4 billion, helping offset biosimilar competition for Stelara.

Business Model and Revenue Drivers

Innovative Medicine includes treatments for cancer, immunology, neuroscience and other areas; several major drugs face biosimilar or generic competition as patents expire.

MedTech includes surgical, orthopedic, cardiovascular and vision products, and has been expanded through acquisitions such as Shockwave Medical.

J&J has a long record of dividend increases and a strong credit rating.

Competitive Landscape

J&J competes with Merck, Pfizer, AbbVie, Roche and others in pharmaceuticals, and with Medtronic, Abbott, Stryker and Boston Scientific in medical devices.

Its diversification across drugs and devices is a strength.

Revenue Growth and Financial Performance

When reviewing Johnson & Johnson's reported results, these measures give the clearest view of growth, profitability and cash generation:

  • Sales by segment and key product
  • Pipeline approvals and launches
  • Operating margin
  • Litigation reserves
  • Dividend and free cash flow

Profitability and Earnings Quality

Revenue growth is only part of the picture. For Johnson & Johnson, it helps to check whether growth comes from higher volumes, higher prices or acquisitions, and whether margins are widening or narrowing as the business scales.

Reported earnings can include one-time items such as restructuring charges, asset sales, tax effects or legal settlements. Separating these from recurring operating results, and comparing like-for-like periods, gives a more reliable view of underlying profitability.

Balance Sheet, Debt and Financial Stability

A review of Johnson & Johnson's financial position starts with cash, total debt, lease obligations and how operating cash flow compares with capital spending. A business that funds its investment from its own cash flow is in a different position from one that relies on borrowing or issuing new shares.

Changes in inventory, receivables and working capital are also worth monitoring, because they can absorb cash and signal shifts in demand before they appear in revenue.

JNJ Stock Valuation Analysis

Measures such as the price-to-earnings ratio, price-to-sales ratio and enterprise value to EBITDA describe how the market is currently pricing Johnson & Johnson relative to its results.

However, a single valuation ratio cannot establish whether a stock is undervalued or overvalued. Earnings quality, free cash flow, margins, competitive position and the growth needed to support the current price all need to be considered together, and compared with similar companies.

Business Outlook and Investment Risks

Management guidance and industry conditions shape expectations for Johnson & Johnson, but guidance is an estimate rather than an established outcome. Several uncertainties are specific to this business:

  • Patent expirations and biosimilar competition
  • Talc-related litigation
  • Drug pricing regulation
  • Integration of acquisitions

How Medicine Revenue Reaches The Company

A medicine's path from manufacturer to patient involves several intermediaries. Wholesalers distribute products to pharmacies, hospitals and other providers, while insurers and pharmacy benefit managers influence coverage and patient access. The list price is therefore different from the amount the manufacturer ultimately records as revenue. Contractual discounts, rebates and other deductions affect the net proceeds associated with a sale. The mix of products, customers and distribution channels can change the relationship between reported sales and the number of treatments supplied.

Accounting for these deductions requires estimates when products are sold, because the final amounts may depend on later claims, contracts or utilization. Readers can examine the revenue recognition and sales deduction disclosures to understand the main categories and how estimates are updated. A change in a rebate accrual can affect the period in which it is recognized, even if the underlying prescriptions occurred earlier. Comparing the stated policies and subsequent adjustments over time helps explain why sales and cash receipts do not necessarily move together.

From Research To Commercial Medicines

Drug development moves through laboratory research, clinical studies and regulatory review before a product can be marketed for an approved use. Clinical trials assess safety and effectiveness in defined patient populations, and their design influences what conclusions can be drawn from the evidence. Approval for one use does not automatically establish approval for every disease or patient group. Companies also conduct further studies to examine additional uses, treatment combinations or longer-term outcomes.

Research spending in an income statement covers a portfolio of projects at different stages, rather than a direct cost attached only to medicines currently sold. Some projects end without reaching the market, while others require continued study after launch. Collaboration agreements can add another layer: a partner may share development costs or receive payments tied to development, sales or royalties. Reading the agreement disclosures alongside research expenses helps distinguish internally funded work from spending and obligations shared with partners.

How Medical Devices Reach Care Settings

Medical devices are often selected through a purchasing process that involves clinicians, hospital administrators and procurement teams. A surgeon's familiarity with an instrument, evidence about clinical outcomes, compatibility with existing equipment and the total cost of a procedure can all matter. Hospitals may negotiate purchasing agreements across groups of products. The decision process can therefore differ from that for a prescription medicine, where coverage rules and pharmacy distribution play a prominent role.

Some device systems combine durable equipment with instruments or supplies used during procedures. This creates different patterns of revenue: equipment purchases may be intermittent, while associated supplies depend more directly on use. Service, training and support can also be part of the commercial relationship. When reviewing device results, it helps to identify which products are capital equipment and which are procedure-related, and to consider how changes in procedure volumes or hospital purchasing practices affect each category.

Reading Acquisition Accounting

An acquisition can add products and research projects to reported results, but the purchase price also creates balance sheet entries. The acquirer allocates the consideration among identifiable assets acquired and liabilities assumed, using estimated fair values. Identifiable intangible assets can include developed technology and intellectual property; goodwill generally represents the portion of the purchase price remaining after the identifiable net assets are recognized. These accounting amounts are distinct from the cash paid for the transaction.

Finite-lived intangible assets are generally amortized over their estimated useful lives, producing expenses after the acquisition closes. Goodwill is not amortized under U.S. accounting rules, but is assessed for impairment. An impairment charge reflects a reduction in an asset's recorded value under the applicable accounting test; it does not itself represent a new cash payment in that period. Acquisition notes, amortization disclosures and cash flow statements together show different aspects of the transaction and its subsequent accounting.

Conclusion: Is JNJ Stock Worth Analyzing in 2027?

Johnson & Johnson has a business model with clear drivers that can be tracked through its reported results, and a set of risks that are specific to its industry and financial position.

A balanced assessment considers growth, profitability, balance-sheet strength, valuation and risk together. JNJ is a company worth monitoring for what its results reveal about its business.

Frequently asked questions

What are J&J's segments?

J&J reports Innovative Medicine and MedTech.

What is Kenvue?

Kenvue is the consumer health company J&J separated in 2023, which owns brands such as Tylenol and Band-Aid.

Why does talc litigation matter?

J&J faces lawsuits over talc products, which can result in large legal costs.